In this issue:
Pembrolizumab + gemcitabine + cisplatin for BTC
Toripalimab + neoadjuvant chemoradiotherapy in locally advanced OESCC
Tislelizumab + chemotherapy vs placebo + chemotherapy for OESCC
Trastuzumab + ramucirumab and paclitaxel for HER2 GOJ
Combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
KIT and PDGFRA mutations of gastrointestinal stromal tumour patients
Pathological CR as a predictor for long-term outcomes of gastric cancer
Neoadjuvant chemotherapy for patients with OESCC
Risk factors for the development of second primary OESCC
Late toxicity of health-related QoL following chemotherapy for OESCC
Please login below to download this issue (PDF)